uniQure to Participate in Multiple Upcoming Industry Conferences in May
uniQure N.V. (NASDAQ: QURE) announced its participation in three upcoming virtual investor and scientific conferences. The Truist Securities Life Sciences Summit is scheduled for May 4-5, 2021, featuring one-on-one meetings. The American Society of Gene and Cell Therapy (ASGCT) virtual event will take place from May 11-14, 2021, showcasing five data presentations, including two oral presentations on May 12 and 13. Finally, at the RBC Capital Markets Global Healthcare Conference on May 18-19, 2021, there will be additional virtual meetings and a fireside chat with CEO Matt Kapusta.
- None.
- None.
Insights
Analyzing...
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 03, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences:
- 7th Annual Truist Securities Life Sciences Summit, May 4 - 5, 2021
- Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Tuesday, May 4.
- Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Tuesday, May 4.
- American Society of Gene and Cell Therapy (ASGCT) Virtual 2021, May 11 - 14, 2021
- uniQure will have a significant presence at ASGCT with five data presentations, of which two are oral presentations including:
- “Clinical Outcomes in Patients With and Without Pre-existing Neutralizing Antibodies to the Vector: 6-Month Data from the Phase 3 HOPE-B Gene Therapy Trial of Etranacogene Dezaparvovec” on Wednesday, May 12, 6:15 – 6:30 p.m. ET.
- “First Proof-of-Concept of miQURETM Based Gene Targeting in the Liver: Lipid Lowering and Atherosclerosis Suppression by AAV-miQURETM-Mediated ANGPTL3 Targeting” on Thursday, May 13, 6:30 – 6:45 p.m. ET.
- “Clinical Outcomes in Patients With and Without Pre-existing Neutralizing Antibodies to the Vector: 6-Month Data from the Phase 3 HOPE-B Gene Therapy Trial of Etranacogene Dezaparvovec” on Wednesday, May 12, 6:15 – 6:30 p.m. ET.
- uniQure will have a significant presence at ASGCT with five data presentations, of which two are oral presentations including:
- 2021 RBC Capital Markets Global Healthcare Conference, May 18 - 19, 2021
- Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Tuesday, May 18.
- A fireside chat with Matt Kapusta, chief executive officer, will take place the same day from 9:10 to 9:35 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
- Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Tuesday, May 18.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com
uniQure Contacts:
| FOR INVESTORS: | FOR MEDIA: | |
| Maria E. Cantor | Chiara Russo | Tom Malone |
| Direct: 339-970-7536 | Direct: 617-306-9137 | Direct: 339-970-7558 |
| m.cantor@uniQure.com | c.russo@uniQure.com | t.malone@uniQure.com |
FAQ
What conferences is uniQure (QURE) participating in May 2021?
When is the Truist Securities Life Sciences Summit for uniQure (QURE)?
What presentations will uniQure (QURE) make at ASGCT 2021?
When is the RBC Capital Markets Global Healthcare Conference for uniQure (QURE)?
Will there be a fireside chat with uniQure's CEO Matt Kapusta?
